Bristol-Myers Squibb Company (BMY) — RQD Stock Rating Cockpit
Bristol-Myers Squibb Company (BMY) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (63/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+185.6% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
Warning: Paper profits outpaced real cash collected while unpaid invoices rose—classic earnings quality red flag.
Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.
Our SEC fine-print scanner flagged elevated accounting or executive-hedging risk combined with interest-rate headwinds.
JEV AI Jury Split (Battleground) on BMY
13.3% ROIC with 71.1% gross margin and 10.24% FCF yield.
Flagged cash-conversion divergence or elevated filing risk disclosures.
Put/Call 0.70x with 22/40 institutional & insider flow.
- ✓Established market leader in Health Care with deep daily trading liquidity.
- !Headline earnings grew much faster than real operating cash flow—watch out for profit revisions.
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring BMY)
- ✓Live walkthrough of BMY's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
BMY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -0.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BMY today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BMY. Explore sector supply chains on /butterfly.
BMY Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDShould I buy, hold, or sell BMY stock right now?
Bristol-Myers Squibb Company (BMY) currently earns a Roarable Rating of D+ (Sell — SELL) with 63/100 RQD Confidence. Accounting Warning: Paper earnings outpaced operating cash flow (+185.6% (NI vs OCF)) as receivables rose.
What is BMY's 12-month price target and RQD AI Jury consensus?
BMY's 12-month base price target is $62.77 (range $48.96 to $74.07), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.